

Supplementary Table 1. Exclusion criteria and number of patients.

Exclusion criteria	Patients (N=125)
Patients with any psychiatric disorder and/or without being in treatment with psychiatric medication and/or who had has not a psychiatric medical visit before the treatment.	109
In IFN-based treatment .	10
Patients with DAAs without completing the treatment, for any reason except for neuropsychiatric symptoms	5
Patients participating in ongoing clinical trials.	1

Supplementary table 2. Clinical data of HCV patients according to the DAAs treatment (number of patients (N)).

Regimen	SOF	SOF+SMV		SOF+LDV		SOF+DCV	OMB/PAR/RTV + DAS	
	With RBV (N= 1)	With RBV (N= 5)	Without RBV (N= 2)	With RBV (N= 3)	Without RBV (N= 31)	With RBV (N= 3)	With RBV (N= 2)	Without RBV (N= 1)
Changes before treatment	-	1	1	1	5	2	1	1
Concomitant intravenous drugs								
Metadone	-	1	-	-	9	1	1	-
Cocaine	-	1	-	-	-	-	-	-
Other drug abuse								
Alcohol	-	1	-	-	-	3	-	-
Cannabis	-	-	-	1	-	2	-	-
Adherence (%)	100	95	97.5	87.5	98	96.7	87.5	100
Sustained viral response N (%)	1 (100)	5 (100)	2 (100)	3 (100)	31 (100)	3 (100)	2 (100)	1 (100)
All adverse drug events								
Tiredness	1	4	1	2	9	1	1	1
Dermatological disorders	-	4	1	1	5	1	-	-
Anorexia	-	1	-	-	1	-	-	-
Gastrointestinal disorders	-	2	-	1	4	1	-	-
Myalgia	-	1	1	2	-	1	-	-
Headache	-	1	-	2	4	1	-	-
Dizziness	-	-	-	-	1	-	-	-
Syndrome Flu-like	-	-	-	-	2	-	-	-
Neuropsychiatric symptoms								
Insomnia	-	2	1	-	5	-	-	-
Depression	-	2	-	1	2	1	-	-
Attention deficits	-	1	-	-	1	-	-	-
Drowsiness	-	1	-	1	2	-	-	-
Agression	-	1	-	-	2	-	-	-
Psychotic disorder	-	-	1	-	1	1	-	-
Irritability	-	-	1	-	5	1	-	-
Hallucinations	-	-	1	-	1	-	-	-
Suicidal ideation	-	-	-	-	1	-	-	-
Medication changes during the treatment								
New drug prescription	-	1	1	-	1	1	-	-
Change of treatment	-	-	-	-	-	1	-	-
Increased dose	-	-	-	-	2	-	-	-
Dose reduction	-	1	1	-	1	-	-	-
Stop the drug	-	-	1	-	-	-	-	-
Emergency consultations	-	-	-	-	2	-	-	-
Hospital admissions	-	-	-	-	2	-	-	-